| Literature DB >> 27387199 |
Karolina Dorniak1, Einar Heiberg2,3, Marcin Hellmann1, Dorota Rawicz-Zegrzda1, Maria Wesierska1, Rafal Galaska4, Agnieszka Sabisz5, Edyta Szurowska5, Maria Dudziak1, Erik Hedström6,7.
Abstract
BACKGROUND: Pulse wave velocity (PWV) is a biomarker for arterial stiffness, clinically assessed by applanation tonometry (AT). Increased use of phase-contrast cardiac magnetic resonance (CMR) imaging allows for PWV assessment with minor routine protocol additions. The aims were to investigate the acquired temporal resolution needed for accurate and precise measurements of CMR-PWV, and develop a tool for CMR-PWV measurements.Entities:
Keywords: Aorta; Applanation tonometry; Magnetic resonance imaging; Phase contrast; Pulse wave velocity; Temporal resolution
Mesh:
Year: 2016 PMID: 27387199 PMCID: PMC4937588 DOI: 10.1186/s12872-016-0292-5
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1The graphical user interface for pulse wave velocity assessment. The oblique sagittal image of the aorta (left) shows the perpendicular flow measurement planes (white lines) in the ascending aorta and at the level of the diaphragm. The centre-line aortic distance between flow planes are shown as a yellow line with cross marks. The graph (right) shows the flow curves and respective upslope tangents with their baseline intersection points giving the time delay between flow curves (∆t; dashed part of the baseline tangent)
Demographic and clinical characteristics of the study population
| Healthy young | Patients |
| |
|---|---|---|---|
| Number of subjects | 13 | 13 | |
| Male/Female | 8/5 | 6/7 | 0.70 |
| Age (years) | 26 (18 – 43) | 61 (52 – 72) | <0.0001 |
| BMI (kg/m2) | 20 (17 – 24) | 27 (22 – 35) | <0.0001 |
| Systolic blood pressure (mmHg) | 120 (100 – 140) | 130 (110 – 160) | 0.02 |
| Diastolic blood pressure (mmHg) | 80 (55 – 80) | 80 (60 – 90) | 0.17 |
| History of smokinga | 0 | 6 | 0.01 |
| History of CAD | 0 | 4 | 0.10 |
| Statins | 0 | 13 | <0.0001 |
| Antihypertensive drugsb | 0 | 12 | <0.0001 |
| Diabetesc | 0 | 2 | 0.48 |
aNo current smoker. b8 patients with ACE inhibitors, of which 1 with added diuretics, 1 with added calcium channel blockers, and 1 with added beta adrenolytics. Four patients with AT receptor blockers, of which 1 with added beta adrenolytics, 1 with added beta adrenolytics and diuretics, and 1 with added beta adrenolytics, diuretics and alpha adrenolytics. cAll patients without insulin dependent diabetes
The PWV median errors for different number of time frames/temporal resolution based on 210 computer phantoms
| Time frames | Temporal resolution [ms] | Median error [m/s] | Median error [%] |
|---|---|---|---|
| 20 | 50.0 | 2.36 | 21.3 |
| 21 | 47.6 | 1.51 | 17.2 |
| 22 | 45.5 | 0.72 | 10.4 |
| 23 | 43.5 | 0.16 | 9.1 |
| 24 | 41.7 | -0.02 | 6.5 |
| 25 | 40.0 | -0.39 | 4.4 |
| 26 | 38.5 | -1.61 | 10.8 |
| 27 | 37.0 | -2.74 | 18.1 |
| 28 | 35.7 | -2.39 | 21.3 |
| 29 | 34.5 | -1.83 | 16.2 |
| 30 | 33.3 | -1.29 | 11.4 |
| 31 | 32.3 | -0.76 | 6.7 |
| 32 | 31.3 | -0.42 | 5.1 |
| 33 | 30.3 | -0.20 | 2.6 |
| 34 | 29.4 | -0.11 | 1.3 |
| 35 | 28.6 | 0.10 | 0.9 |
| 36 | 27.8 | 0.48 | 3.6 |
| 37 | 27.0 | 0.46 | 4.1 |
| 38 | 26.3 | 0.30 | 3.0 |
| 39 | 25.6 | 0.23 | 2.4 |
| 40 | 25.0 | 0.17 | 1.8 |
Errors are expressed as median errors for all velocities in the range of 2–20 m/s
Fig. 2Median percentage PWV errors for number of time-frame samples for flow data from 210 computer phantoms. For clarity, 4 cases representative of different PWV are shown. All computer phantoms were however used for cut-off calculations. A plateau in the median PWV error is found from 35 time frames per cardiac cycle, corresponding to a temporal resolution of at least 30 ms at a heart rate of 60 beats per minute (top). The grey vertical line represents the cut-off 35 time frames, and the grey horizontal lines indicate the maximum PWV errors (±6 %) above the cut-off 35 time frames. The median error for 35 time frames was 0.27 ± 0.32 m/s between calculated and true PWV in phantoms, and is visualised in the identity plot (bottom). The dashed line indicates line of identity
PWV by AT and CMR
| AT-PWV (m/s) | CMR-PWV (m/s) |
| |
|---|---|---|---|
| Healthy young | 5.6 ± 0.7 | 4.5 ± 0.8 | <0.0001 |
| Patients | 9.0 ± 2.2 | 7.8 ± 2.2 | 0.07 |
|
| <0.0001 | <0.0001 |
Fig. 3Bland-Altman plots showing intra- (top) and interobserver (bottom) CMR-PWV variability. Intraobserver variability for CMR-PWV was low for all 3 observers, 0 ± 0.03 m/s (15 years; left), -0.04 ± 0.33 m/s (4 years; middle), and -0.02 ± 0.30 m/s (<1 year; right), respectively. The interobserver variability was also generally low, for 4 vs. 15 years -0.01 ± 0.32 m/s (left), <1 vs. 15 years 0.01 ± 0.30 m/s (middle), and <1 vs. 4 years 0.02 ± 0.38 m/s (right). Dotted lines indicate mean differences and dashed lines represent 95 % limits of agreement
Fig. 4Bland-Altman plots showing AT-PWV vs. CMR-PWV. The AT-PWV overestimated CMR-PWV by 1.1 ± 0.7 m/s in younger healthy subjects (left) and by 1.6 ± 2.7 m/s in patients (right). Dotted lines indicate mean differences and dashed lines represent 95 % limits of agreement. Also note the PWV differences between younger healthy subjects and older patients where PWV is lower and less dispersed in healthy young subjects